HCM City Drug Firm Sells Shares (Vietnam)
This article was originally published in PharmAsia News
Executive Summary
Imexpharm, one of Vietnam's leading drug companies, sold shares to two major investment funds. Vietnam Fund Management bought a 6 percent stake in the company while Vietnam Holding purchased a 2 percent interest. The sale is part of Imexpharm's efforts to raise their chartered capital from VN$92 billion (U.S.$5.7 million) to VN$112 billion. Imexpharm already boasts an impressive growth rate of 30 percent a year. In the first 10 months of 2007, it reported a gross profit worth VN$54 billion. Representatives for Imexpharm are hopeful the new alliances will help the company develop relationships with more partners and improve its corporate governance practices. (Click here for more
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.